Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Intelligent Medicine Original Medical Technology
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Early-stage biotech leveraging AI platform TranProteins for protein/peptide drug design; has developed GLP-1 receptor agonist; focusing on experimental validation of solubility, affinity, and activity.[1][3][5]
- Therapeutic areas
- EndocrinologyRheumatologyGastroenterology
- Modalities
- PeptidesProtein
- Industry
- Biotech
02
Partnerships
WuXi BiologicsNutshell TherapeuticsBeiGenePi HealthRuijin HospitalRenji HospitalWest China HospitalBeijing University of Chinese Medicine
Beyond the preview
Go deeper on Intelligent Medicine Original Medical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intelligent Medicine Original Medical Technology.